Treatment of hyaline membrane disease in the preterm newborn with exogenous lung surfactant. A controlled study;Estudio controlado del tratamiento de la enfermedad de membrana hialina del recién nacido pretérmino con surfactante pulmonar exógeno (porcino vs. bovino)

Gaceta Medica de Mexico

Volumn 141, Issue 4, 2005, Pages 267-271

  Sánchez Mendiola, Melchor ^a,c   Martínez Natera, Octavio C ^b   Herrera Maldonado, Nazarea ^b   Ortega Arroyo, Jesús ^b  

^a Hospital Central Militar   (Mexico)

^b Universidad del Ejército y Fuerza Aérea   (Mexico)

^c Hospital Militar   (Mexico)

Author keywords

Hyaline membrane disease; Newborn respiratory distress syndrome; Premature infant; Pulmonary surfactants

Indexed keywords

BERACTANT; LUNG SURFACTANT; PORCINE SURFACTANT; SURFACEN; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HYALINE MEMBRANE DISEASE; LUNG ALVEOLUS; LUNG DISEASE; MALE; MORTALITY; NEWBORN; OPEN STUDY; OXYGENATION; PREMATURITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

APGAR SCORE; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; HYALINE MEMBRANE DISEASE; INFANT, NEWBORN; LENGTH OF STAY; MALE; OXYGEN; OXYGEN INHALATION THERAPY; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; TIME FACTORS;

EID: 24344479287     PISSN: 00163813     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Fujiwara T, Maeta H, Chida S et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980;1:55-59.
2. Jobe AH, Ikegarni M. Surfactant for the treatment of respiratory distress syndrome. Am Rev Resp Dis 1987;136:1256-1275.
3. Arizmendi-Dorantes JG, Camarero-Benítez CC. Sindrome de insuficiencia respiratoria neonatal. Experiencia de cinco años en el Hospital Central Militar de México (1980-1984). Rev Sanid Milit Méx 1987;41:151-155.
4. Jobe AH. Pulmonary surfactant therapy. N Engl J Med 1993;328:861-868.
5. Soll RF. Natural surfactant extract vs. synthetic surfactant in the treatment of established respiratory distress syndrome (Cochrane Review). En: The Cochrane Library, Issue 3, 2003.Oxford. Update Software.
6. Speer CP, Gefeller O, Groneck P et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995;72:F8-13.
7. Long WA, Zeng G, Henry GW. Pharmacologic adjuncts II: Exogenous surfactants. En: Assisted Ventilation of the Neonate. Goldsmith JP, Karotkin EH (Eds.) VM Saunders Co. 3a. Edition Philadelphia, 1996. p. 305-325.
8. Rosello JO, Hayward PE, Martell M et al. Hyaline membrane disease (HMD) therapy in Latin America: impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. J Perinat Med 1997;25:280-287.
9. López-Candiani C, Valencia-Salazar G, Rodríguez-Weber M. Enfermedad por membranas hialinas. Epidemiología en el Instituto Nacional de Pediatría. Acta Ped Mex 1994;15:169-174.
10. Clements JA, Avery ME. Lung surfactant and neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998;157:S59-S66.
11. Kattwinkel J, Surfactant: evolving issues. Clin Perinatol 1998;25:17-32.
12. Dekowski SA, Holtzman RB. Surfactant replacement therapy. Pediatr Clin North Am 1998;45:549-571.